Loading organizations...

§ Private Profile · Philadelphia, PA, USA
Biotech company developing its Synecta™ platform for cell and gene therapy manufacturing, focused on cell activation and expansion.
BlueWhale Bio is a Philadelphia, Pennsylvania-based biotechnology company that develops manufacturing technology to address supply bottlenecks in cell and gene therapies. The organization focuses on its proprietary Synecta platform, which improves the efficiency of cell activation and expansion during the early stages of the manufacturing process. The enterprise has raised a total of $23 million in capital, including an $18 million seed financing round in 2023 and an additional $5 million in 2025. This financial backing was provided by a syndicate of institutional investors that includes Danaher Ventures, Novalis LifeSciences, and Marshall Wace. By optimizing downstream processes to make these specialized treatments more accessible to patients, the company successfully reached its first clinical trial in under eighteen months from its inception. BlueWhale Bio was founded in 2022 by Carl June and James Riley.
BlueWhale Bio has raised $18.0M across 1 funding round.
BlueWhale Bio has raised $18.0M in total across 1 funding round.
BlueWhale Bio has raised $18.0M in total across 1 funding round.
BlueWhale Bio's investors include Murali Venkatesan, Marshall Wace, Novalis LifeSciences.
BlueWhale Bio has raised $18.0M across 1 funding round. Most recently, it raised $18.0M Seed in September 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 8, 2023 | $18M Seed | Murali Venkatesan | Marshall Wace, Novalis LifeSciences | Announced |